Tryptophan levels may explain why some migraine drugs fail

NCT ID NCT07177885

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at why over 20% of migraine patients don't respond well to triptans, a common migraine medication. Researchers will compare tryptophan and related substances in the blood of 144 people who either respond or don't respond to triptans. The goal is to understand the biological reasons behind treatment failure, which could lead to better personalized migraine care in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors personalize migraine treatments based on a patient's tryptophan levels.

What could go wrong

This is an observational study, not a treatment trial. It may not lead to any immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, France

    Contact

    Contact Email: •••••@•••••

    Contact